| Literature DB >> 35419254 |
Benjamin W Schlichtmann1,2, Monica Hepker3, Bharathi N Palanisamy3, Manohar John4,2, Vellareddy Anantharam5,2, Anumantha G Kanthasamy3,2, Balaji Narasimhan1,2, Surya K Mallapragada1,2.
Abstract
Synucleinopathies are a subset of debilitating neurodegenerative disorders for which clinically approved therapeutic options to either halt or retard disease progression are currently unavailable. Multiple synergistic pathological mechanisms in combination with the characteristic misfolding of proteins are attributable to disease pathogenesis and progression. This complex interplay, as well as the difficult and multiscale nature of therapeutic delivery into the central nervous system, make finding effective treatments difficult. Nanocarriers (NCs) are a class of materials that can significantly improve therapeutic brain delivery and enable multifunctional therapies. In this review, an update on the known pathology of synucleinopathies is presented. Then, NC-enabled therapeutics designed to target the multiple mechanisms by combination therapies and multiscale targeting methods is reviewed. The implications of these strategies are synthesized and evaluated to suggest opportunities for the rational design of anti-neurodegenerative NC therapeutics.Entities:
Keywords: Neurodegeneration; drug delivery; nano
Year: 2021 PMID: 35419254 PMCID: PMC9004679 DOI: 10.1016/j.coche.2021.100673
Source DB: PubMed Journal: Curr Opin Chem Eng ISSN: 2211-3398 Impact factor: 5.163